Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL28146998 | 0.97 | MAPT (0.36) | MAPTTSHRKDM4EALDH1A1 | |
| Allyl Alcohol SCHEMBL18426956 | 0.88 | TSHR (0.53) | MAPTTSHRKDM4EALDH1A1PYCR1 | |
| Alcohol SCHEMBL3256403 | 0.88 | — | — | |
| SCHEMBL43114 | 0.87 | — | — | |
| SCHEMBL4177390 | 0.87 | — | — | |
| Propanol SCHEMBL27781756 | 0.87 | TSHR (0.33) | MAPTTSHRKDM4EALDH1A1 | |
| Methyl Alcohol SCHEMBL27760189 | 0.85 | — | — | |
| Hydroxyamine SCHEMBL27886493 | 0.85 | — | — | |
| Ammonia Solution, Strong SCHEMBL15060108 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL2427941 | 0.84 | PYCR1 (0.33) | TSHRALDH1A1PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1768966-A1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | Infinity Pharmaceuticals, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2006009869-A1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-4384968-A | TREATING GAS STREAM WITH MORPHOLINE OR SERIVATIVE | BETZ LABORATORIES, INC. (US) | 1983-05-24 | — | — | US | disclosed |
| EP-0018084-B1 | METHOD FOR REMOVING PARTICLES FROM PARTICLE-LADEN GAS STREAM | BETZ EUROPE, INC. (US) | 1983-04-13 | — | — | EP | disclosed |
| EP-0052435-A1 | Electrostatic precipitator efficiency enhancement | BETZ EUROPE, INC. (US) | 1982-05-26 | — | — | EP | disclosed |
| US-4294588-A | MORPHOLINE ADDITIVE AS ANTIAGGLOMERANT | BETZ LABORATORIES, INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4239504-A | Free base amino alcohols as electrostatic precipitator efficiency enhancers | BETZ LABORATORIES, INC. (US) | 1980-12-16 | — | — | US | disclosed |
| US-4118439-A | IONICALLY CROSSLINKED QUATERNARY AMMONIUM POLYMER | RHONE-POULENC S.A. (FR) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | MAPT 3860/4885TSHR 4345/4885KDM4E 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.